Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/12/24
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger AgreementBusiness Wire • 09/10/24
ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIMBusiness Wire • 08/19/24
ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.GlobeNewsWire • 07/27/24
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIMPRNewsWire • 07/26/24
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIMGlobeNewsWire • 07/03/24
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public ShareholdersPRNewsWire • 06/24/24
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI PharmaceuticalsGlobeNewsWire • 06/24/24
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to ShareholdersBusiness Wire • 06/24/24
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/04/24
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/14/24
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkGlobeNewsWire • 03/19/24